A raft of updates on the R&D pipelines in the adenosine niche, plus a biotech company interview
Beyond KRAS G12C inhibitors, there are plenty of other related targets to consider including KRAS::SOS1 and SHP2
Six key strategic factors to consider going forward in the quest for future oncology R&D pipelines
A look at BET-bromodomain inhibitors, PROTACs, stapled proteins and more on MYC
What can we learn about the MYC transcription factor and oncogene in order to turn it into a viable target in oncology R&D?
Thoughts and commentary on the Jounce-Celgene collaboration update and the emerging ICOS landscape
A review of our Top 10 sarcoma results from ASCO19 plus commentary from a specialist KOL in this niche
Amgen have a large early phase 1 oncology pipeline including bispecifics, BiTEs, a CAR and small molecules. What can we learn from recent data presented?
Insights on the updated phase 1b clinical data evaluating Neon's personalized vaccine NEO-PV-01 in combination with nivolumab in advanced cancers?
What can we learn from the recent data presented on Affimed's innate bispecific platform? A candid conversation with CEO, Dr Adi Hoess
Next generation IO molecules are likely to feature bispecific antibodies - can we address the weaknesses seen with immune agonist antibodies by switching modalities?
Can mRNA disrupt cancer therapy and boost responses beyond what we see with checkpoint therapy?
How is Synthorx's IL-2 cytokine THOR-707 different from other compounds in this niche?
How the design of different cancer approaches can affect clinical performance
Can we employ red blood cells in allogeneic, off-the-shelf cellular therapy products for the treatment of cancer?
Update on PTCL developments and a possible new therapy that may be approved in this setting
Working out which are markers versus valid targets is going to be key in IO progress. Here we look at one particular candidate...
Exploring the many challenges associated with targeting KRASG12C and why we should temper enthusiasm for this niche
A review of the latest available TLR data and a look at an emerging biotech Silverback Therapeutics in this niche
Proteins change shape, both temporally and also in response to different conditions. Can we use this information to develop novel cancer therapeutics? One company is exploring ways of achieving this.
A look at inducing apoptosis of cancer cells via CDK7 inhibition and the future for rational combo approaches.
How next generation immunotoxin approaches can overcome capillary leak syndrome and be effective anti-cancer agents
Gritstone have evolved from start-up biotech to clinical stage oncology company. We catch up with them and discuss their latest progress.
Can gamma delta T cells be effective as a therapeutic in GBM?
Is there a better way to target myeloma than with BCMA alone? Data suggests there's plenty of room for improvement.
A look a the updated adenosine pathway landscape and how it is progressing
As look at ways of targeting 𝞬𝝳 T cells, we may need to consider whether or not the situation is immunosuppressive or proliferative
Neutrophils may be responsible for inducing immunosuppression and resistance to checkpoint therapies so how do we target them in the clinic?
We've heard much about PARP inhibitors but they aren't the only targets in DDR we can hit...
With the help of a leading pathologist, we examine the challenges associated with PD-L1 and TMB as biomarkers for patient selection
Having a companion diagnostic is important for precision medicine, but can they accurately predict who is most likely to respond to cancer immunotherapy?
Mobbed posters indicate attendee interest, but is it justified?
A look at Apexigen's anti-CD40 data in advanced pancreatic cancer - hit or miss?
What are the emerging trends from AACR19? What can we expect to see emerge over the next year?
Preview of AACR19 in Atlanta and what you need to know about ten novel cancer targets with data at the meeting.
In the second part of our review of the AACR19 cancer immunotherapy program, we take a look at more noteworthy sessions in Atlanta.
First part of a look at the immune-oncology track at AACR19 - there's a LOT going on this year!
Can we make novel allogeneic cell therapies with γδ T cells? We find out!
Can γδ T cells be employed as a therapeutic against cancer?